Article Text

PDF
Transcleral delivery of triamcinolone acetonide and ranibizumab to retinal tissues using macroesis
  1. Rishi P Singh1,
  2. Michael Ellen Mathews2,
  3. Michael Kaufman2,
  4. Alan Riga2
  1. 1Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
  2. 2Buckeye Ocular LLC, Cleveland, Ohio, USA
  1. Correspondence to Dr Rishi P Singh, Cole Eye Institute, 9500 Euclid Avenue, Desk i32, Cleveland, OH 44195, USA; singhr{at}ccf.org

Abstract

Aim To determine the feasibility of macroesis for the delivery of ranibizumab and triamcinolone acetonide via a transcleral route.

Methods Macroesis is a non-invasive method of drug delivery that uses alternating current (AC) to deliver drugs to target tissues. Two preclinical models of drug delivery were used for feasibility studies of delivering ranibizumab and triamcinolone acetonide to ocular tissues. In the first model, full-thickness sections of rabbit ocular tissue (conjunctiva to retina) were placed on an interdigitated electrode platform, and the drug was placed on the surface of the tissue. A non-uniform electrical field was applied to the ocular tissue, and electrical conductivity, a measurement of drug delivery, was monitored during the course of the experiment. In a second model, termed a ‘simulated vitreous model,’ the same full-thickness sections of rabbit ocular tissue were mounted below the electrode device, and the test compounds were placed on the electrodes. The fluid below the tissue, which simulated the vitreous cavity, was analysed using UV spectroscopy at the end of the study for the presence of drug.

Results In the electrical conductivity studies, the electric characteristics of the tissue–drug system clearly showed movement of the drug through the tissue to the dielectric sensor based on changes in the electrical conductivity of the tissue sample with triamcinolone. No change in tissue conductivity was observed when no drug was placed. No heat generation occurred during the course of the study; nor was any gross tissue destruction noted. In the simulated vitreous model, studies using triamcinolone yielded concentrations ranging from 0.280 to 0.970 mg/ml, depending on the voltage, frequency and time applied. In as little as 6.7 min, clinically efficacious doses could be obtained in the preclinical system. Studies using ranibizumab yielded concentrations of 0.070–0.171 mg/ml, depending on the voltage, frequency, and time applied. In as little at 6.7 min, 92.8% throughput could be achieved.

Conclusion Successful delivery of ranibizumab and triamcinolone acetonide can be achieved with macroesis in preclinical studies.

  • Retina
  • drugs
  • pharmacology
  • experimental and laboratory

Statistics from Altmetric.com

Footnotes

  • Presented at the American Society of Retina Specialist Meeting, Maui, Hawaii, 2008 and the Retina Society Meeting, Palm Springs, California.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.